|
|
Post by blindhog1 on Jul 18, 2015 20:47:27 GMT -5
My ENDO has approved me taking Afrezza even with me in this study. I have to take the Spiometry test next week then fill my Rx. Today my A1C was 7.4, so that is my starting point. Everything remains the same, but I will take 8 units at dinner. It appears he will adjust my study night time dosage as we progress.
The funny part of this is my ENDO is going to meetings to teach local Dr's about prescribing Afrezza. He has known I was an investor and was waiting for me to see him so he could prescribe TO ME.
**************************************************************
I posted this on the Yahoo MB on 7/14/15. One of the individuals requested a Proboards thread. So this is the beginning. I'm pretty consistent so I'm looking for an A1C in the 6's in ninety days. I hope folks aren't bored with my progress. Another thing is the 5 year study I'm in has been going on for about 2 years. If I am correct and my ENDO is correct Afrezza could very well throw my study results (and its company) for a loop. It shouldn't take long to find out. |
|
|
|
Post by peppy on Jul 18, 2015 21:02:17 GMT -5
Welcome Blindhog.
|
|
|
|
Post by liane on Jul 18, 2015 21:04:20 GMT -5
Hi Blindhog,
What is the study you are in?
|
|
|
|
Post by blindhog1 on Jul 18, 2015 21:17:13 GMT -5
Study title: A trial comparing cardiovascular safety of insulin degludec versus insulin glardine in subjects with T2 diabetes at high risk of cardiovascular events. SPONSOR: Novo Nordisk
Basically this is a substitute for Lantus. I had been taking Lantus for several years. I'm study participant NUMBER 0001. |
|
|
|
Post by Chris-C on Jul 18, 2015 21:17:20 GMT -5
Thanks for sharing Blindhog. Welcome to the board! Good to hear your Endo is an Afrezza prescribing physician. I'm fascinated that including Afrezza would be consistent with the study design protocol, but not knowing the specifics, I'll assume that your physician knows what s/he is doing.
Chris C
|
|
|
|
Post by blindhog1 on Jul 18, 2015 21:42:37 GMT -5
Chris, I'm seen monthly for the study and I never figured I could be included in anything Afrezza related till it was over. My ENDO is a major regional researcher and trainer. He and I have been discussing Afrezza for a couple of years. He knows me very well and knows I know the ends and outs of absolutely everything going on in the field of Diabetes. I'm a great historian and study participant.
So that is exactly what my concern was when I went for my 6 month check. He stated that I would be an absolutely perfect candidate. Since what I'm taking is so similar to Lantus there is no reason to exclude me. SO.............watch this space. If it works for me I get to go to some of the meetings with him and Social Media will have another major poster. Let's see what this brings. |
|
|
|
Post by peppy on Jul 18, 2015 21:47:33 GMT -5
Blindhog, what part of the country are you located? What age is your ENDO? |
|
|
|
Post by robsacher on Jul 18, 2015 21:59:17 GMT -5
blindhog, Would you and your endocrinologist be willing to answer some questions in regard to a new Seeking Alpha article that I would like to have published? I am looking for a doctor who has a lot of experience in the diabetic field willing to participate. I can send the questions via email to the doctor and yourself. Most of the questions would be for the doctor and I think it will take the doctor about twenty minutes of her or his time. I have had several articles previously published. Please go to this link to reply to this message and lick the "send message" button on the left side of the page. seekingalpha.com/author/robert-sacherBest wishes, Robert Sacher |
|
|
|
Post by blindhog1 on Jul 18, 2015 22:19:48 GMT -5
Robert I don't mind answering your question in the open. I would think everyone would understand. When I saw him on Tuesday I pondered asking him if I could post his name on Twitter or other Social Media because of his stance on the future of Afrezza. I came to the conclusion, personally, that that would be a bad idea for him.
I've read all your articles and you have a positive outlook on MNKD, but you also know the craziness of those on the other side of this stock. I put nothing past them. He doesn't need that on a personal or professional basis.
I don't care, but I'm not in the eye of this storm. |
|
|
|
Post by robsacher on Jul 18, 2015 22:32:11 GMT -5
blindhog,
I understand. It's odd to realize that doctors are under political pressure to refrain from discussing what may be a break through advancement in the medical field. In a nutshell, this is an example of the power aligned against MannKind.
You would think that we were asking them to discuss why the Earth is no longer known to be at the center of the universe. Now I have an inkling of how Galileo must have felt.
Good luck with your endeavors and please keep us informed of your progress.
Best wishes,
RS
|
|
|
|
Post by blindhog1 on Jul 18, 2015 22:41:46 GMT -5
Robert, the difference between publishing a professional paper and Seeking Alpha is night and day. I would hope everyone on ProBoards knows the financial implications of Afrezza succeeding. We all know it works........but succeeding......World Wide is the goal. And doing that will cost the Medical establishment hundreds of BILLIONS a year because it will save lives and limbs and time. Hospital utilization will be down. How can we survive with a healthy population?
You bet I'm on board this train. |
|
|
|
Post by kc on Jul 18, 2015 23:51:42 GMT -5
Well stated.
|
|
|
|
Post by babaoriley on Jul 19, 2015 1:37:21 GMT -5
Welcome, "blindhog1" - well, I guess that's a reasonable facsimile for "guinea pig 0001," which came to me immediately when I read your first post. I hope the MD's amongst us can share with their theories as to the rationale of your Afrezza-leaning Endo including Afrezza in a study about another type of insulin, which apparently is a Novo product. The non-doctors sure can't, but perhaps it has something to do with the "high risk of cardiovascular events" condition. Sorry you're in that category, hang in there and let us know how it goes.
|
|
|
|
Post by ashiwi on Jul 19, 2015 6:38:35 GMT -5
Interesting that the Sponsor is Novo and that they are using Afrezza in the trial.
Afrezza dosing is prior to each meal. This study has it administered only at dinner.
A1c would be lower if the Afrezza is used prior to each meal, the way it's meant to be used.
|
|
|
|
Post by kball on Jul 19, 2015 8:18:53 GMT -5
Study title: A trial comparing cardiovascular safety of insulin degludec versus insulin glardine in subjects with T2 diabetes at high risk of cardiovascular events. SPONSOR: Novo Nordisk
Basically this is a substitute for Lantus. I had been taking Lantus for several years. I'm study participant NUMBER 0001. Leave it to smartest folks in the room to make Heart Attacks sound like attending some sort of charity gala. |
|
